抗体药物偶联物在三阴性乳腺癌中的应用

曾铖; 张剑

doi:10.3877/cma.j.issn.1674-0807.2024.03.002

中华乳腺病杂志(电子版) >

2024 , Vol. 18 >Issue 03: 140 - 145

DOI: https://doi.org/10.3877/cma.j.issn.1674-0807.2024.03.002

专家论坛

抗体药物偶联物在三阴性乳腺癌中的应用

曾铖 ¹ ,
张剑 ^,¹^,^†

展开

^1.200032　上海，复旦大学附属肿瘤医院肿瘤内科；复旦大学上海医学院肿瘤学系

通信作者：张剑，Email: jianz@fudan.edu.cn

收稿日期: 2024-03-22

网络出版日期: 2024-07-03

版权

未经授权，不得转载、摘编本刊文章，不得使用本刊的版式设计，除非特别声明，本刊刊出的所有文章不代表中华医学会和本刊编委会的观点。本刊为电子期刊，以网刊形式出版。

收起

Application of antibody-drug conjugate in triple negative breast cancer

Cheng Zeng ¹ ,
Jian Zhang ^,¹^,^†

Expand

^1.Department of Medical Oncology, Shanghai Cancer Center, Fudan University, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China

Corresponding author: Zhang Jian, Email: jianz@fudan.edu.cn

Received date: 2024-03-22

Online published: 2024-07-03

Copyright

No content published by the journals of Chinese Medical Association may be reproduced or abridged without authorization. Please do not use or copy the layout and design of the journals without permission.

All articles published represent the opinions of the authors, and do not reflect the official policy of the Chinese Medical Association or the Editorial Board, unless this is clearly specified.

Fold

摘要

三阴性乳腺癌(TNBC)由于其独特的病理学特征和高度异质性，相较于其他亚型乳腺癌具有更高的恶性程度和较差的预后，因此亟需开发新型且高效的治疗方法。近年来，抗体药物偶联物(ADC)因其高选择性和显著的抗肿瘤活性，逐渐成为研究热点，并在TNBC的治疗中取得了一些重要进展。本文介绍了ADC在TNBC领域的研究进展，重点介绍了以Trop-2、HER家族和其他靶点为目标的ADC药物，包括戈沙妥珠单克隆抗体(SG)、datopotamab deruxtecan(Dato-DXd)、SKB264、德曲妥珠单克隆抗体(DS-8201)、维迪西妥单克隆抗体(RC48)、patritumab deruxtecan(HER3-DXd)等。总结了这些药物在临床试验中的疗效和安全性数据，讨论了其在提高TNBC患者生存期和生活质量方面的潜力，分析了当前ADC治疗存在的挑战和未来研究方向，强调了探索ADC药物的耐药机制及其与其他治疗策略组合的重要性。未来，通过不断优化和创新，ADC有望为TNBC患者带来更有效的治疗选择。

关键词： 抗体药物偶联物; 三阴性乳腺癌; 临床研究

本文引用格式

曾铖 , 张剑 . 抗体药物偶联物在三阴性乳腺癌中的应用[J]. 中华乳腺病杂志(电子版), 2024 , 18(03) : 140 -145 . DOI: 10.3877/cma.j.issn.1674-0807.2024.03.002

Abstract

Triple negative breast cancer (TNBC) exhibits higher malignancy and poorer prognosis compared with other breast cancer subtypes due to its unique pathological characteristics and high heterogeneity. Therefore, there is an urgent need to develop new and effective treatment methods. In recent years, antibody-drug conjugates (ADCs) have become a research hotspot due to their high selectivity and significant antitumor activity, achieving remarkable progress in TNBC treatment. This paper reviews the research progress of ADCs in the field of TNBC, focusing on ADCs targeting Trop-2, the HER family, and other factor, including sacituzumab govitecan (SG), datopotamab deruxtecan (Dato-DXd), SKB264, trastuzumab deruxtecan (DS-8201), disitamab vedotin (RC48) and patritumab deruxtecan (HER3-DXd). The efficacy and safety data of these drugs in clinical trials are summarized, and their potential in improving the survival and quality of life of TNBC patients is discussed. Additionally, the current challenges and future research directions of ADC therapy are analyzed, with an emphasis on the mechanisms of resistance to ADC drugs and their combinations with other therapies. With continuous optimization and innovation, ADCs are expected to provide more effective treatment options for TNBC patients in the future.

Key words： Antibody-drug conjugate; Triple negative breast cancer; Clinical research

参考文献

原文顺序 | 文献年度倒序 | 文中引用次数倒序

[1]	Chau CH, Steeg PS, Figg WD. Antibody-drug conjugates for cancer[J]. Lancet, 2019, 394(10200): 793-804.

[2]	Tarantino P, Carmagnani Pestana R, Corti C, et al. Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies[J]. CA Cancer J Clin, 2022, 72(2): 165-182.

[3]	Derakhshan F, Reis-Filho JS. Pathogenesis of triple-negative breast cancer[J]. Annu Rev Pathol, 2022, 17: 181-204.

[4]	Li Y, Zhang H, Merkher Y, et al. Recent advances in therapeutic strategies for triple-negative breast cancer[J]. J Hematol Oncol, 2022, 15(1): 121.

[5]	Qi C, Gong J, Li J, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results[J]. Nat Med, 2022, 28(6): 1189-1198.

[6]	Jabbarzadeh Kaboli P, Shabani S, Sharma S, et al. Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates[J]. Am J Cancer Res, 2022, 12(4): 1671-1685.

[7]	Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer[J]. N Engl J Med, 2019, 380(8): 741-751.

[8]	Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer[J]. N Engl J Med, 2021, 384(16): 1529-1541.

[9]	Xu B, Ma F, Wang T, et al. A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments[J]. Int J Cancer, 2023, 152(10): 2134-2144.

[10]	Gradishar WJ, Moran MS, Abraham J, et al. Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2022, 20(6): 691-722.

[11]	中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2021版)[J]. 中国癌症杂志，2021, 31(10)：1007-3639.

[12]	中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)乳腺癌诊疗指南(2022版)[M]. 北京：人民卫生出版社，2022.

[13]	European Society for Medical Oncology. ESMO metastatic breast cancer living guideline[EB/OL].[2024-03-15].

[14]	Okajima D, Yasuda S, Maejima T, et al. Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells[J]. Mol Cancer Ther, 2021, 20(12): 2329-2340.

[15]	Aditya B, lan EK, Funda MB, et al. Datopotamab deruxtecan (Dato-Dxd) in advanced triple-negative breast cancer (TNBC): updated results from the phase 1 TROPION-PanTumor01 study[EB/OL].[2024-03-15].

[16]	Schmid P． Datopotamab deruxtecan (Dato-DXd) ＋ durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): updated results from BEGONIA, a phase Ib/II study[EB/OL].[2024-03-15].

[17]	Cheng Y, Yuan X, Tian Q, et al. Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132[J]. Front Oncol, 2022, 12: 951589.

[18]	Yongmei Y，Xinhong W，Quchang O，et al. Updated efficacy and safety of SKB264 (MK-2870) for previously treated metastatic triple negative breast cancer (mTNBC) in phase 2 study[EB/OL].[2024-03-15].

[19]	Modi S, Park H, Murthy RK, et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study[J]. J Clin Oncol, 2020, 38(17): 1887-1896.

[20]	Tarantino P, Viale G, Press MF, et al. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer[J]. Ann Oncol, 2023, 34(8): 645-659.

[21]	Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, A novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1[J]. Clin Cancer Res, 2016, 22(20): 5097-5108.

[22]	Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-Low advanced breast cancer[J]. N Engl J Med, 2022, 387(1): 9-20.

[23]	Shi F, Liu Y, Zhou X, et al. Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy[J]. Drug Deliv, 2022, 29(1): 1335-1344.

[24]	Wang JY, Liu YJ, Zhang QY. RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: a pooled analysis of two studies[EB/OL].[2024-03-15].

[25]	Gandullo-Sánchez L, Ocaña A, Pandiella A. HER3 in cancer: from the bench to the bedside[J]. J Exp Clin Cancer Res, 2022, 41(1): 310.

[26]	Koyama K, Ishikawa H, Abe M, et al. Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression[J]. PLoS One, 2022, 17(5): e0267027.

[27]

Krop

, Masuda

, Mukohara

, et al. Patritumab deruxtecan (HER3-DXd), a human epidermal growth factor receptor 3-directed antibody-drug conjugate, in patients with previously treated human epidermal growth factor receptor 3-expressing metastatic breast cancer: a multicenter, phase I/II trial[J]. J Clin Oncol, 2023, 41(36): 5550-5560.

[28]	Hamilton EP，Ololade D, Mythili S，et al. A phase 2 study of HER3-DXd in patients (pts) with metastatic breast cancer (MBC)[EB/OL].[2024-03-15].

[29]	Taylor KM. The LIV-1 subfamily of Zinc transporters: from origins to present day discoveries[J]. Int J Mol Sci, 2023, 24(2)：1255.

[30]	Sussman D, Smith LM, Anderson ME, et al. SGN-LIV1A: a novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer[J]. Mol Cancer Ther, 2014, 13(12): 2991-3000.

[31]	Tsai M, Han HS, Montero AJ，et al. Weekly ladiratuzumab vedotin monotherapy for metastatic triple-negative breast cancer[EB/OL].[2024-03-15].

[32]	Han H, Diab S, Alemany C，et al. Open label phase 1b/2 study of ladiratuzumab vedotin in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer[EB/OL].[2024-03-15].

[33]	Podojil JR, Miller SD. Potential targeting of B7-H4 for the treatment of cancer[J]. Immunol Rev, 2017, 276(1): 40-51.

[34]	Wu J，Zhang J，Li H，et al. First-in-human/phase I trial of HS-20089, a B7-H4 ADC, in patients with advanced solid tumors[EB/OL].[2024-03-15].

[35]	Chatterjee S, Sinha S, Kundu CN. Nectin cell adhesion molecule-4 (NECTIN-4): a potential target for cancer therapy[J]. Eur J Pharmacol, 2021, 911: 174516.

[36]	Challita-Eid PM, Satpayev D, Yang P, et al. Enfortumab vedotin antibody-drug conjugate targeting Nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models[J]. Cancer Res, 2016, 76(10): 3003-3013.

[37]	Zhou W, Fang P, Yu D, et al. Preclinical evaluation of 9MW2821, a site-specific monomethyl auristatin E-based antibody-drug conjugate for treatment of Nectin-4-expressing cancers[J]. Mol Cancer Ther, 2023, 22(8): 913-925.

Options

文章导航

模态框（Modal）标题

摘要

本文引用格式

Abstract

参考文献